#Merimepodib was originally developed by Trek Therapeutics. BioSig's majority-owned subsidiary, NeuroClear Technologies, acquired rights to the experimental drug... ViralClear Pharmaceuticals, to develop the drug. #Stocks #biotech

https://t.co/SkkASKMoFl